.Pharmacolibrary.Drugs.ATC.A.A02BC04 .Pharmacolibrary.Drugs.ATC.A.A02BC04| name: | Rabeprazole |
| ATC code: | A02BC04 | route: | oral |
| n-compartments | 1 |
Rabeprazole is a proton pump inhibitor (PPI) used to reduce gastric acid production. It is commonly prescribed for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and other conditions involving excess stomach acid. The drug is approved and widely used today.
Pharmacokinetic parameters reported for healthy adult volunteers following a single oral dose under fasting conditions.
Jeong, SH, et al., & Lee, YB (2023). Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic-Pharmacodynamic Modeling. Biomedicines 11(11) –. DOI:10.3390/biomedicines11113021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38002021
Sheng, YC, et al., & Zheng, QS (2010). Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. European journal of clinical pharmacology 66(11) 1165–1169. DOI:10.1007/s00228-010-0892-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20838991
Litalien, C, et al., & Faure, C (2005). Pharmacokinetics of proton pump inhibitors in children. Clinical pharmacokinetics 44(5) 441–466. DOI:10.2165/00003088-200544050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15871633